Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-10-02, Stock:PFE, The news for the past five days is as follows:
2019-09-25: NEWS1: Protalix Completes Enrollment in Third Fabry Disease Study.NEWS2: Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023.
2019-09-26: NEWS1: Pfizer buys Durham facility as expansion plans continue to unfold.
2019-09-27: NEWS1: Mylan Misled Investors Over EpiPen Pricing Probe, SEC Says.NEWS2: Growth stocks vs. value stocks.NEWS3: Dow flat despite gains for Walgreens Boots, Pfizer shares.NEWS4: Nektar Stock Down on Disappointing Breast Cancer Study Data.NEWS5: Dow Jones Today: Stocks Turn Mixed, Consumer Spending Data Weak, Wells Fargo Gets A New CEO.NEWS6: UPDATE 1-Pfizer veteran Ian Read to retire as executive chairman.NEWS7: Pfizer Inc. Awards “Golden Tickets” to Neutrolis and Mediar Therapeutics.NEWS8: Dow Jones Today: Futures Rise Ahead of Data, Apple Heads For Hollywood.NEWS9: Ian Read to retire as Pfizer executive chairman.NEWS10: Ian Read to Retire as Executive Chairman of Pfizer’s Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman.NEWS11: The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave.NEWS12: Pfizer shares up 1.3% premarket after reporting positive results in second trial of dermatitis treatment.NEWS13: Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis.NEWS14: Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug.
2019-09-30: NEWS1: Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know.NEWS2: Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen.NEWS3: Pfizer, Walgreens, UnitedHealth, Dow, 3M Are 5 Worst Dow Jones Stocks This Year.NEWS4: Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study.NEWS5: Company News For Sep 30, 2019.NEWS6: California investor buys 67,000-square-foot facility in Durham.NEWS7: Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer.
2019-10-01: NEWS1: As Buyout Fever Grows, Alexion, Amarion and BioMarin Are Potential Targets.NEWS2: Why the Earnings Surprise Streak Could Continue for Pfizer (PFE).NEWS3: AstraZeneca/Merck's Lynparza Positive in Prostate Cancer Study.NEWS4: LabCentral gets state, private funds for new biomanufacturing lab space.

Answer: Decrease